UDCA to protect kidneys during partial nephrectomy
Treatments studied
Part of Cancer, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This clinical trial is testing whether a medicine called ursodeoxycholic acid (UDCA) can help protect the kidneys during partial nephrectomy (removing only the tumor while keeping the healthy part of the kidney). It is for people with early-stage kidney tumors who will have temporary interruption of blood flow to the kidney during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a kidney tumor (stage T1) and are scheduled for surgery to remove only part of the kidney.
- You are between 18 and 75 years old.
- Your kidney function (eGFR) is 30 or higher.
- You don't have a history of allergy to the study drug (UDCA) or certain bile acid medicines.
- You haven't had major surgery on your kidney or a kidney transplant in the past.
- You are not taking certain medicines (like strong antibiotics or bile acid drugs) that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a 3D kidney model made with artificial intelligence helps surgeons remove a kidney tumor (partial nephrectomy) more precisely. It may help preserve healthy kidney tissue while treating the cancer.
This trial uses a special computer model to predict how well your kidneys will work after surgery to remove part of a kidney (partial nephrectomy). It may help doctors plan better care for people with early-stage kidney tumors.
This study tests a robot-assisted surgery to remove part of the kidney for T1 tumors without clamping the main artery, which may help preserve kidney function. It may be an option for patients who are healthy enough for major surgery and have a small, early-stage kidney tumor.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Hear when a new Kidney Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.